News

MGD006 is a humanized, Dual-Affinity Re-Targeting (DART(R)) bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. The study,

The double-blind and placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics of single oral doses of Debio 1450 in healthy subjects. Debio 1450 is an anti-infective agent

In partnership with Sanofi, Merrimack completed an extensive Phase II program for MM-121 which was designed to assess the role of ErbB3 in a number of cancer indications

Kala has initiated dosing in its Phase III trial (KPI-121-C-001) to evaluate the safety and efficacy of LE-MPP in managing inflammation and pain associated with cataract surgery. In

Proceeds from the financing will be used to augment Navitor’s proprietary drug discovery platform and accelerate the development of a pipeline of novel drugs that target cellular nutrient

GlycoMimetics is initially exploring the clinical use of the drug candidate to treat acute myeloid leukemia (AML) following preclinical studies of GMI-1271 for blood cancers and other cancers

Out of an abundance of caution, CDC is taking aggressive steps to protect the health of all involved, including providing protective courses of antibiotics for potentially exposed staff.

The ceftolozane/tazobactam is being developed to treat complicated urinary tract and intra-abdominal infections. The submission of NDA is supported by the positive data from two pivotal Phase 3

The decision was taken as the studies showed that orteronel plus prednisone could extend the time patients lived before their cancer progressed but failed to extend overall survival